Evolus Broadens Its International Presence with Nuceiva Launch in Great Britain

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, launched commercial operations in Great Britain and shipped the first customer orders for Nuceiva (botulinum toxin type A) last month. 

 

The Evolus Innovator and Evolus Early Adopter education programs for healthcare professionals are underway, and interest is high as customers gain their first experiences of using Nuceiva.

 

“Worldwide, the aesthetics market sector continues to rapidly evolve. We are excited to introduce Nuceiva to Great Britain, the single largest market for aesthetic neurotoxins in the European region, while we continue to finalize plans for entering additional countries as part of a phased rollout,” said David Moatazedi, president and CEO, Evolus. “Europe is the second largest market for aesthetic neurotoxins globally, and our expansion there will form the foundation for a potential future portfolio of aesthetic products.”

 

In the UK, Evolus is partnering with Wigmore Medical, known as a leading supplier of specialist products to aesthetics practitioners. Wigmore has been working in aesthetics for over 35 years, providing reliable pharmacy services and expertise, trusted by practitioners. Evolus plans to introduce Nuceiva next in Germany and Austria in the first half of 2023, and is working closely with its partner, Novvia Pharm. Novvia was established in 2003 and is dedicated to providing leading brands to medical aesthetics practitioners in Germany and Austria. During 2023, the company expects to enter additional European countries, and, subject to regulatory approval, will also launch Nuceiva in Australia.

 

“It’s refreshing to have a new type of aesthetics company to engage with,” said Dr. David Eccleston, founder and medical director at MediZen Clinics, and lead investigator for the Nuceiva PAS study. “When I integrate any new treatment into my practice, I look for robust clinical data, exceptional manufacturing and deep expertise. Having options means I can tailor treatments to meet the needs of my patients.”

 

“Starting commercialization in one of Europe’s biggest aesthetics markets gives practitioners another choice in the neuromodulator they offer to their patients,” said Dan Stewart, vice president and general manager, Evolus International. “Our tiered training programs offer credentialed customers the opportunity to learn more about Nuceiva, including the unique aspects of the product and how this translates into results for patients. With support from our distributor partners and pharmacies, we are looking forward to evolving the future of beauty with our customers.”

 

Nuceiva (botulinum toxin type A) is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact in adults below 65 years of age. The safety and efficacy of Nuceiva was evaluated through the company’s Transparency program, the largest head-to-head pivotal study versus Botox to date.